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ABSTRACT. 
 
Cytochrome P450 family 1 (CYP1) enzymes catalyze the metabolic activation of environmental 
procarcinogens such as benzo[a]pyrene, B[a]P, into carcinogens, which initiate the process of 
carcinogenesis. Thus, stopping the metabolic activation of procarcinogens can possibly prevent the 
onset of cancer. Several natural products have been reported to show unique ability in inhibiting CYP1 
enzymes. We found that khellin, a naturally occurring furanochromone from Ammi visnaga, inhibits 
CYP1A1 enzyme with an IC50 value of 4.02 µM in CYP1A1-overexpressing human HEK293 
suspension cells. To further explore this natural product for discovery of more potent and selective 
CYP1A1 inhibitors, two sets of semisynthetic derivatives were prepared. Treatment of khellin with 
alkali results in opening of a pyrone ring, yielding khellinone (2). Claisen-Schmidt condensation of 
khellinone (2) with various aldehydes in presence of potassium hydroxide, at room temperature, provide 
a series of furanochalcones 3a-v (khellinochalcones). Treatment of khellinone (2) with aryl aldehydes in 
presence of piperidine, under reflux, affords the flavanone series of compounds 4a-p 
(khellinoflavanones). The khellinoflavanone 4l potently inhibited CYP1A1 with IC50 value of 140 nM 
in live cells, with 170-fold selectivity over CYP1B1 (IC50 for CYP1B1 = 23.8 µM). Compound 4l at 3 x 
IC50 concentration for inhibition of CYP1A1, completely protected HEK293 cells from CYP1A1-
mediated B[a]P toxicity. Lung cancer cells, A549 (p53+) and Calu-1 (p53-null), blocked in growth at the 
S-phase by B[a]P were restored into the cell cycle by compound 4l. The results presented herein 
strongly indicate the potential of these khellin derivatives for further development as cancer 
chemopreventive agents.   
 
KEYWORDS. Khellin; cytochrome P50 family 1 enzymes; CYP1A1; khellinone; flavanones; 
polycyclic aromatic hydrocarbons; cancer chemoprevention. 
INTRODUCTION 
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Ammi visnaga  (commonly known as 'Khella'; Family: Apiaceae) is a widespread flowering plant 
native to Europe, Asia, and North Africa, and has many therapeutic properties.1 The khella seeds are 
being used in traditional medicine for respiratory conditions including bronchitis, asthma, and cough.2 
The seeds of this plant contain a γ-pyrone, furanochromone khellin as a major constituent, which is a 
vasodialator, and antispasmodic.1a, 3 Inspired from the vasodialatory and antispasmodic property of 
khellin, Roger Altounyan, an Anglo-Armenian physician discovered cromoyln sodium, a chromone 
class of antiasthma drug.4 Khellin has also been extensively studied for its cardioactive properties, and 
is being used for angina pectoris therapy.5 Based on the cardioactive property of khellin, the Labaz 
company from Belgium, have discovered anti-arrhythmic drug amiodarone6 via medicinal chemistry on 
benzofuran scaffold. Other known pharmacological activities of khellin and its derivatives includes 
melanin-inhibition,1d, 7 anti-inflammatory,8 anticancer,9 and cancer chemopreventive activity.10 
Many natural compounds and their derivatives modulate the expression and activities of cytochrome 
P450 family 1 (CYP1) enzymes which are known to bioactivate procarcinogens.11 The cytochrome 
P450 proteins comprise a large family of enzymes that can catalyze the oxidative metabolism of a 
variety of xenobiotic chemicals including toxic compounds, drugs and chemical carcinogens as well as 
endogenous compounds. As a part of our continuing efforts to discover CYP1A1 inhibitors as cancer 
chemopreventive agents;12 the furanochromone khellin (1) was identified as a selective CYP1A1 
inhibitor (CYP1A1 IC50 = 4.02 µM, CYP1B1 IC50 = 34.6 µM) via screening of institutional natural 
products repository (Figure 1).10 
To further explore this natural product for fine-tuning its potency and selectivity profile, 
semisynthetic modifications were carried out. Literature reports indicated that semisynthetic 
modifications of khellin have been performed earlier,13 however, never been explored as cancer 
chemopreventive agents. Herein, we report synthesis of two series of khellin derivatives 
(khellinochalcones and khellinoflavanones) and their biological evaluation as CYP1A1 inhibitors and 
possible cancer chemopreventive agents. 
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The in-vivo studies14 have demonstrated that CYP1A1 is involved in benzo[a]pyrene, B[a]P-induced 
carcinogenesis in mice. These studies have also shown that polycyclic aromatic hydrocarbon (PAH)-
treated mice overexpresses CYP1A1 in lungs and liver. Therefore, herein we also studied the ability of 
khellin derivatives to protect lung cancer cells and normal cells from B[a]P-induced toxicity. 
 
Figure 1. Structure of khellin (1), its CYP1A1, CYP1B1 inhibitory activity, and interactions with 
CYP1A1 active site. The H-bonding is shown by dark blue dotted lines, whereas π- π interactions by 
light-blue dotted lines. 
   
RESULTS AND DISCUSSION 
Synthesis of khellin derivatives. The khellin was identified as one of the 'hit' (active) from the 
natural products repository screening,10 in the search of new leads for cancer chemoprevention. 
However, the level of activity was in a micromolar range (IC50, 4.02 µM); therefore it was necessary to 
modify the structure of khellin to modulate its ability to inhibit CYP1A1. Based on the structural 
features of khellin, it was decided to convert khellin to khellinone followed by its condensation with 
aryl aldehydes. The presence of acetyl group in khellinone provides an easiest handle for chemical 
modifications. 
O
OMe
OMe
O
O
Khellin (1)
CYP1A1: 4.02 µM
CYP1B1: 34.6 µM Phe 224
Thr 497
Heme
Asp320
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Khellin (1) was treated with potassium hydroxide in ethanol, resulting in formation of khellinone 
(2).15 Two series of compounds were prepared from khellinone (2);16 (a) chalcones by the Claisen-
Schmidt condensation of khellinone with different substituted aryl aldehydes; and (b) furanoflavanones 
by treatment of khellinone with aryl aldehydes in presence of piperidine. The khellinone (2) was treated 
with aryl aldehydes under alkaline condition (KOH), at room temperature, to obtain khellinochalcones 
3a-v (Figure 2, path b). Interestingly, with slight modifications in the reaction conditions (base and 
reaction temperature), the another series of products were formed. Khellinone (2), when it was reacted 
with aryl aldehydes in ethanol with catalytic amounts of piperidine (instead of KOH), under reflux 
conditions, it yielded furanoflavanones 4a-p (khellinoflavanones) (Figure 2 path c). Mechanistically, the 
flavanones were formed via cyclization of chalcones. All synthesized compounds were characterized 
based on their spectroscopic properties. The coupling constant of newly formed bond (C8-C9) in 
chalcones was found to be 16 Hz, which confirmed the trans-orientation of the double bond. The 1H 
NMR spectrum of flavanone 4b showed the signals of H-7 at δ 5.45 ppm and H-6 at δ 3.04 and 2.94 
ppm confirming the formation of flavanone skeleton. Further, the 13C NMR and DEPT135 spectrum 
confirmed the appearance of extra -CH2 at δ 45.0 (C-6), and a -CH at δ 78.4 (C-7). Interestingly, when 
khellinone (2) was treated with thiophene-2-carboxaldehyde, it underwent double aldehyde coupling, 
producing product 4p. The 1H NMR of 4p did not show presence of signal for CH2, however, the extra 
proton appeared at δ 7.13 ppm indicating the presence of an additional olefinic proton. 
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Figure 2. Synthesis of khellin derivatives 3a-v and 4a-p. Reagents and conditions (a) KOH (1M), 
ethanol, 80 °C, 12 h, 61%; (b) RCHO (R = aryl or heteroaryl), KOH (1 M), methanol, 0 °C to rt, 12-14 
h, 40-85%; (c) RCHO (R = aryl or heteroaryl), piperidine, ethanol, reflux at 70 °C, 12 h, 51-68%. The 
'R' groups of different derivatives 3a-v and 4a-p are shown in Table 1 and 3. 
 
The pyridyl-furanochalcone derivative 3g is a pan-inhibitor of CYP1 family enzymes. A series of 
furanochalcones 3a-v were tested for inhibition of CYP1A1 in yeast microsomes (Sacchrosomes™) and 
human live HEK293 cells, overexpressing CYP1A1, at 10 µM (Table 1).10, 12 The parent natural product 
khellin (1) showed 88% and 81% inhibition of CYP1A1, at 10 µM, in the two assays. Several chalcone 
derivatives showed higher inhibition of CYP1A1 in both assays. The furanochalcone 3a, bearing a 
simple phenyl ring (as R group) showed 92% and 97% inhibition of CYP1A1 in the microsomal and 
live cells assays. This result was expected, as chalcones have been reported to possess potent CYP1A1 
inhibition activity.12a The most potent derivative among the series of chalcones was the compound 3g, 
which bears a pyridin-3yl moiety as R group. This compound showed 97% and 99% inhibition of 
CYP1A1 in Sacchrosomes™ and in live human cells, respectively. The results of in-vitro CYP1A1 
inhibition by furanochalcones in Sacchrosomes™ and HEK293 cells, at 10 µM concentration, are shown 
in Table 1. 
 
 
Table 1.  In-vitro CYP1A1 inhibition by furanochalcones in SacchrosomesTM and HEK293 cells, 
overexpressing CYP1A1, at 10 µM concentration.  
 
Entry 
O
OMe
OMe
O
OH
R
R = 
% inhibition of CYP1A1 at 10 μM 
(Mean  ± SD) b 
Sacchrosomes™ HEK293 cells 
1 - 88.3 ± 4.3 81.3 ± 2.1 
2 - 47.5 ± 3.3 81.1 ± 3.3 
3a - Ph 91.6 ± 3.5 96.6 ± 4.5 
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3b - Ph (4-Br) 26.8 ± 2.3 57.7 ± 1.7 
3c - Ph (4-Cl) 77.5 ± 2.8 85.7 ± 2.1 
3d - Ph (3-Br,4-F) 83.1 ± 3.3 82.3 ± 2.1 
3e - Ph (4-F) 92.4 ± 3.6 89.5 ± 2.2 
3f - Ph (2,4-di-F) 23.9 ± 2.2 85.4 ± 2.8 
3g - pyridin-3-yl 97.2 ± 3.8 99.2 ± 3.3 
3h - Ph (4-OMe) 28.9 ± 2.3 55.7 ± 1.8 
3i - Ph (2,6-di-Cl) 19.6 ± 1.8 58.8 ± 1.8 
3j - Ph (2-OEt,5-Br) 64.3 ± 2.8 31.7 ± 1.5 
3k - Ph (2-Cl) 23.6 ± 2.1 19.5 ± 0.8 
3l - Ph (2,3-di-OMe) 15.2 ± 1.5 21.6 ± 0.9 
3m - Ph (2,4-di-OMe) 10.2 ± 1.1 22.9 ± 0.9 
3n - Ph (penta-F) 21.9 ± 1.8 71.6 ± 2.4 
3o - Ph (3-Br,4-OMe) 37.0 ± 2.4 74.0 ± 2.1 
3p - Ph (2,4,5-tri-OMe) 92.2 ± 3.5 96.8 ± 3.9 
3q - Ph (3,4-methylene-dioxy) 48.4 ± 2.7 -1.1 ± 2.1 
3r - thiophen-3-yl 95.1 ± 3.6 79.4 ± 2.8 
3s - Ph (2,4-di-Cl) 80.2 ± 3.3 71.4 ± 2.5 
3t - Ph (2-F) 49.7 ± 2.6 -2.1 ± 2.1 
3u - naphthalen-2-yl 41.1 ± 2.6 0.2 ± 2.6 
3v - anthracen-2-yl 43.4 ± 2.6 -1.1 ± 3.5 
ANFa - 97.1 ± 2.6 30.2 ± 10.8 
aANF (α-naphthoflavone) was used as a positive control. b The percentage inhibition values represent 
mean and standard deviations (± SD) of results obtained from two independent experiments.  
 
The IC50 values were then determined for selected furanochalcones in a panel of enzymes belonging to 
cytochrome P450 sub-families 1, 2, and 3. The results are shown in Table 2. Chalcones 3e (bearing 4-
fluoro-phenyl as R group) and 3p (bearing 2,4,5-tri-OMe phenyl as R group) displayed highly selective 
inhibition of CYP1A1 with IC50 value of 0.32 and 0.30 µM, respectively. These two compounds do not 
inhibit the other two enzymes from CYP1 sub-family, i.e. CYP1A2 or CYP1B1 (IC50 > 10 µM). 
Further, they do not inhibit the CYP2 and CYP3 sub-family of enzymes commonly involved in drug 
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metabolism (Table 2). The pyridyl furanochalcone 3g showed inhibition of Sacchrosomes™ containing 
CYP1A1, CYP1A2 and CYP1B1 with IC50 values of 0.34, 0.17 and 0.66 µM, respectively; whereas no 
inhibition of CYP2 and CYP3 sub-family of enzymes was observed (IC50 > 20 µM). The compound 3g 
showed IC50 values of 0.47 and 0.27 µM for CYP1A1 and CYP1B1 inhibition in live human cell assays. 
 
Table 2.  IC50 values of selected furanochalcones in a panel of CYP enzymes in Sacchrosomes™ 
 
Entry 
IC50 in µM (Sacchrosomes™)a 
1A1 1A2 1B1 2A6, 2B6, 2C8, 2C9, 2C18, 2C19, 
2D6, 2E1, 3A4 
3e 0.32 ± 0.04 >10 >10 >20 
3g 0.34 ± 0.03 0.17 ± 0.02 0.66 ± 0.04 >20 
3p 0.30 ± 0.05 >20 >20 >20 
3r 0.28 ± 0.03 4.2 ± 0.8 0.78 ± 0.04 >20 
aThe IC50 values represent average (± standard deviations) of results obtained from three independent 
experiments. 
 
The in-silico docking studies have shown that the chalcone 3g displays H-bonding and π-π 
interactions with the active site residues of CYP1A1. The carbonyl oxygen of the chalcone 3g showed 
three-way H-bonding interactions with Asp 320, Thr 497 and Asn 222 residues, whereas the pyridine 
ring displays π-π stacking with Phe 224 and Phe 258 residues. The furan ring of the chalcone 3g has 
been oriented towards the heme of the CYP1A1 enzyme (Figure 3), as it was observed in case of khellin 
(Figure 1). 
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Figure 3. The interactions of chalcone 3g with CYP1A1 (PDB ID: 4I8V) active site. The H-bonding is 
shown by dark blue dotted lines, whereas π- π interactions by light-blue dotted lines. 
 
The furanoflavanone derivative 4l is a potent and selective inhibitor of CYP1A1 enzyme. A 
series of furanoflavanones 4a-p were tested for inhibition of CYP1A1 enzyme borne on yeast 
microsomes (Sacchrosomes™) and CYP1A1-overexpressing HEK293 cells, at 10 µM concentration 
(Table 3). Several flavanone derivatives showed >85% inhibition of CYP1A1 enzyme in 
Sacchrosomes™ as well as in live human cells overexpressing CYP1A1. The compound 4a, bearing a 
simple phenyl as R group, has shown 97% and 87% inhibition of CYP1A1 in Sacchrosomes™ and in 
live human cells, respectively. The 3-pyridyl substituted flavanone (compound 4e) also showed potent 
inhibition of CYP1A1 enzyme in both assay systems.  
 
 
 
 
Table 3.  In-vitro CYP1A1 inhibition by furanoflavanones in Sacchrosomes™ and HEK293 suspension 
cells, overexpressing CYP1A1, at 10 µM concentrations.a 
 OMe OOMe O
 
% inhibition of CYP1A1 at 10 μM 
Phe 258Phe 224
Asn 222
Thr 497
Asp320Heme
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Entry 
R = (Mean  ± SD) b 
 
Sacchrosomes™ 
 
HEK293 cells 
4a - Ph 97.0 ± 2.4 87.4 ± 3.4 
4b - Ph (2-Br) 97.0 ± 3.1 98.5 ± 2.1 
4c - Ph (3,4-methylene-dioxy) 78.1 ± 1.4 74.1 ± 3.4 
4d - Ph (5-Br, 2-OMe) 87.8 ± 3.9 72.6 ± 5.2 
4e - pyridin-3-yl 96.8 ± 3.2 87.0 ± 2.5 
4f - thiophen-3-yl 79.9 ± 0.4 44.3 ± 4.7 
4g - Ph (4-NO2) 48.1 ± 2.9 -1.5 ± 2.9 
4h - Ph (2-Cl) 87.1 ± 0.9 56.9 ± 6.2 
4i - Ph (2,4-di-Cl) 94.3 ± 2.3 72.6 ± 3.5 
4j - naphthalen-2-yl 71.7 ± 4.2 72.2 ± 2.7 
4k - Ph (2,6-di-Cl) 75.6 ± 1.2 54.1 ± 2.4 
4l - Ph (3-Br,4-F) 96.2 ± 1.8 89.4 ± 1.3 
4m - Ph (2-F) 97.1 ± 1.4 77.8 ± 3.1 
4n - Ph (4-F) 94.2 ± 1.5 79.5 ± 2.3 
4o - Ph 60.7 ± 0.5 0.4 ± 2.4 
4p -thiophene-3-yl 95.8 ± 4.2 68.5 ± 2.9 
ANF - 97.1 ± 2.6 30.2 ± 10.8 
aThe IC50 values represent average (± standard deviation) of results obtained from three independent 
experiments. 
 
Next, the IC50 values were determined for three best flavanones, in live human cell assays expressing 
specific CYP enzymes. Compound 4a was found to be a dual inhibitor of CYP1A1 and CYP1B1 with 
slight selectivity towards CYP1B1. However, the compounds 4e and 4l were selective CYP1A1 
inhibitors, showing 9.2 and 170-fold selectivity over CYP1B1 (Table 4). These compounds does not 
inhibit CYP1A2, CYP2D6 and CYP3A4 (IC50 > 10 µM). The excellent selectivity profile of flavanone 
4l against CYP2D6, CYP3A4 and also within the CYP family 1 enzymes, indicated its potential for 
further exploration. 
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Table 4.  IC50 values of selected furanochalcones for CYP1A1, CYP1A2, CYP1B1, CYP2D6 and 
CYP3A4 inhibition in live human HEK293 cells 
 
Entry 
IC50 in µM (live cells)a 
CYP1A1 CYP1A2 CYP1B1 CYP2D6 CYP3A4 
4a 1.84 ± 0.14 >10 0.566 ± 0.08 >10 >10 
4e 0.45 ± 0.06 >10 4.16 ± 0.25 >10 >10 
4l 0.14 ± 0.04 >10 23.8 ± 1.2 >10 >10 
aThe IC50 values represent average (± standard deviation) of results obtained from three independent 
experiments. 
 
The in-silico docking studies of flavanone 4l with CYP1A1 have shown that it display interactions 
similar to chalcone 3g; however, the molecule was found to be flipped by 180° inside the active site. 
The furan ring of chalcone 3g was oriented towards the heme, whereas it is away from heme in case of 
flavanone 4l. However, despite this flip, the three-way H-bonding interaction of carbonyl oxygen with 
Asp 320, Thr 497 and Asn 222 residues was common in both the inhibitors.  The flavanone 4l also 
showed two π-π stacking interactions with Phe 224 and Phe 258 residues. The interactions of 4l with 
CYP1A1 are shown in Figure 4.  
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Figure 4. The interactions of flavanone 4l with CYP1A1 (PDB ID: 4I8V) active site. 
 
On comparison of the CYP1A1 and CYP1B1 inhibition data of naphthyl pyridochalcones published 
earlier by us,17 with the data of khellinochalcones and khellinoflavanones, an interesting structure-
activity relationship was observed. The 3-pyridyl naphthyl chalcone17 (structure shown in Figure 5) has 
been reported as potent and selective CYP1B1 inhibitor with an IC50 value of 4 nM, showing selectivity 
over CYP1A1. The replacement of naphthyl ring with 4,7-dimethoxybenzofuran has resulted in 
improved CYP1A1 inhibitory activity (Figure 5). The 4,7-dimethoxybenzofuran ring bearing 3-pyridyl 
chalcone 3g showed CYP1A1 inhibition with IC50 value of 470 nM. Compound 3g inhibited CYP1B1 
in live human cell assay with an IC50 of 270 nM, indicating slight selectivity towards CYP1B1. 
Furthermore, when the chalcone skeleton was cyclized in the form of a flavanone (3g versus 4e), there 
was a huge gain in CYP1A1 selectivity. This indicated that flavanones have better selectivity towards 
CYP1A1, compared with chalcones. Interestingly, when the pyridyl ring of flavanone 4e was replaced 
with substituted phenyl, the potent and selective CYP1A1 inhibitor 4l was identified. The compound 4l 
bearing 3-bromo-4-fluorophenyl ring instead of 3-pyridyl (of 4e), inhibited CYP1A1 with IC50 value of 
Phe 258
Phe 224
Asn 222
Thr 497
Asp320Heme
4.0 Å
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140 nM, and 170-fold selectivity over CYP1B1 (IC50 for CYP1B1 = 23.8 µM). The CYP1A1 and 
CYP1B1 activities of chalcones and flavanones, indicating selectivity within these two enzymes, is 
depicted in Figure 5. 
O
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O
N
4e
CYP1A1: 450 nM
CYP1B1: 4160 nM
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O
O
Br
F
4l
CYP1A1: 140 nM
CYP1B1: 23800 nM
CYP1A1: 795 nM
CYP1B1: 4 nM
Compound 6j from ref. 17
CYP1A1 selective inhibitor
CYP1B1 selective inhibitor
 
Figure 5. Structure-activity relationship between chalcones and flavanones.  
 
Furanochalcone 3g and furanoflavanone 4l protect CYP1A1-overexpressing normal human 
cells from CYP1A1 mediated B[a]P toxicity. CYP1A1 is an aryl hydroxylase which provides 
metabolic activation of polycyclic aromatic hydrocarbons (PAHs) and polyhalogenated aromatic 
hydrocarbons (PHAHs). It is mainly expressed in the extrahepatic tissue like lung, placenta, skin etc.18 
The CYP1A1 enzyme is known to metabolically activate benzo[a]pyrene to its carcinogenic form.18-19 
Therefore, to investigate the potential of identified CYP1A1 inhibitors to stop the process of metabolic 
activation, thereby protecting normal cells from carcinogenesis, the B[a]P toxicity in normal HEK293 
cells and HEK293 cells,20 overexpressing CYP1A1, was studied.10, 12 The EC50 of B[a]P in normal 
HEK293 cells was found to be 14 µM, whereas in CYP1A1 overexpressing cells, it was highly toxic 
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(EC50 1.4 µM), indicating that CYP1A1 metabolizes B[a]P to its toxic form. The co-treatment of these 
CYP1A1 overexpressing cells with CYP1A1 inhibitors 3g or 4l, at their 3 x IC50 concentrations, 
resulted in nullifying of B[a]P toxicity. The cells were completely protected from B[a]P toxicity as 
indicated by restoration of the B[a]P EC50 to normal (i.e. 14 µM) (Figure 6). 
 
Figure 6. Protection of CYP1A1-overexpressing HEK293 cells from B[a]P toxicity. B[a]P was used in 
the concentration range of 0.05 µM – 100 µM, in the presence of 3 x IC50 values of the compounds 3g or 
4l  (as determined in the human cell assay where cells expressed CYP1A1 when they were grown in 
suspension). The cell viability was determined by MTT assay. The cell viability determination using 
sulforhodamine B (SRB) assay21 provided similar results to the MTT assay. EC50 values are presented in 
µM concentrations, and represents the average of three independent experiments (***P < 0.001).  
 
Furanoflavanone 4l prevents B[a]P-mediated S-phase block in human lung cancer cells, A549 
and Calu-1. The human lung cancer cell lines A54922 and Calu-123 are known to express CYP1A1 
enzyme. Furthermore, the in vivo studies in mice model14 have shown that PAH-treated mice 
overexpress CYP1A1 in lung tissues; therefore lung cancer cell lines were chosen for this study. The 
effect of CYP1A1 inhibitors on the cell cycle, in the presence of B[a]P, was investigated by first pre-
treating A549 (ATCC CCL-185) and Calu-1 (ATCC HTB-54) lung cancer cells (which express 
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CYP1A1; Figure 7A) with the most potent CYP1A1 inhibitor, compound 4l, and then exposing cells to 
B[a]P. The endogenous CYP1A1 is expected to metabolize B[a]P to its diol-epoxide (BPDE) and 
corresponding O-quinone, products which are known to intercalate DNA. DNA-intercalation should 
block cells primarily at the S phase of the cell division cycle. It has been suggested that DNA-adduct 
formation cause DNA mutations that lead to the onset of cancer.24  
Upon exposure of asynchronous A549 and Calu-1 lung cancer cells (Figures 7B and E) to a 15 µM 
concentration of B[a]P for 3 h and then releasing cells into fresh medium for 57 h, the cells did face a 
block at the S phase of the cell cycle (Figures 7C and F). This would be expected if the CYP1A1 protein 
(Figure 7A), expressed within A549 and Calu-1cells, were to be a functional enzyme. However, when 
cells were at first pre-incubated for 20 h with the CYP1A1-specific inhibitor, compounds 4l, at its 3x 
IC50 concentrations, and then treated with a 15 µM concentration of B[a]P for 3 h, followed by release 
into fresh medium, the cells were preponderantly released from the block (Figures 7D and G). This 
would imply that CYP1A1-mediated metabolism of B[a]P in A549 and Calu-1 cells has been prevented 
by compound 4l, demonstrating the efficacy of the compound in preventing B[a]P-mediated toxicity in 
lung cancer cells.  
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Figure 7. Western blot and FACS analyses of A549 and Calu-1 lung cancer cells. (A)Expression of 
CYP1A1, in 5 µg of total protein, isolated from A549 (lane 1), Calu-1cells (lane 3), normal HEK293 
cells (lane 2; as negative control) and normal WI-38 cells (lane 4; as negative control) was confirmed by 
Western blotting; CYP1A1-bearing SacchrosomesTM (1pmol) were taken as positive control (lane 5). 
The CYP1A1-specificantibody, used for confirming CYP1A1 expression in the upper panel, was from 
ProteinTech(#13241-1-A); beta-actin was used as a loading control and the blot (lower panel) was 
probed with an antibody from Sigma (# A2228). (B) and (E): FACS analyses of untreated A549 (B) and 
Calu-1 cells (E)growing asynchronously. FACS analyses of A549 cells, treated with B[a]P, in the 
absence of compound 4l(C) and in the presence of compound 4l (D). FACS analyses of Calu-1 cells, 
treated with B[a]P, in the absence of compound 4l(F) and in the presence of compound 4l (G).The 
percentage of cells in G0/G1, S and G2/M phases of the cell division cycle is shown in the upper right-
hand corner of each of the FACS analyses. 
1   2      3      4   5(A)
(B) G0/G1: 50.3
S: 24.9
G2/M: 19.2
(C) G0/G1: 23.9
S: 44.5
G2/M: 29.6
G0/G1: 45.3
S: 31.8
G2/M: 13.2
(D)
(E) G0/G1: 56.1
S: 20.7
G2/M: 18.4
(F) G0/G1: 20.3
S: 44.9
G2/M: 32.8
(G) G0/G1: 48.4
S: 26.5
G2/M: 23.1
CYP1A1
β-Actin
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CONCLUSION 
In summary, we have identified that the semisynthetic modifications on the natural product khellin 
has resulted in significant improvement in its CYP1A1 inhibitory activity. The furanochalcone 
derivative 3g and furanoflavanone derivative 4l displayed potent inhibition of CYP1A1 with IC50 values 
of 470 and 140 nM, respectively. These inhibitors completely protected normal human cells from the 
toxicity of procarcinogen B[a]P via inhibition of its metabolic activation. Moreover, compound 4l also 
prevented manifestation of B[a]P-mediated S-phase block (i.e. DNA-intercalation that occurs at S-phase 
upon B[a]P treatment) in lung cancer cells. Thus, the leads identified herein have potential for further 
investigation as cancer chemopreventive agents. 
 
EXPERIMENTAL SECTION 
General. The commercially available khellin was purchased from Sigma Aldrich (CAS: 82-02-0, 
Lot≠ BCBJ3836U). NMR spectra were recorded on Bruker-Avance DPX FT-NMR 500 and 400 MHz 
instruments. Chemical shift values for protons/ carbons are reported in parts per million (ppm) 
downfield from tetramethylsilane. ESI-MS and HRMS spectra were recorded on Agilent 1100 LC-Q-
TOF and HRMS-6540-UHD machines. IR spectra were recorded on Perkin-Elmer IR 
spectrophotometer. Melting points were recorded on digital melting point apparatus.  
The purity of all derivatives was determined using HPLC analysis. The sample solution of compounds 
of concentration 0.5 mg/ml prepared in acetonitrile and filtered through 0.45 μ membrane filter injected 
(15 μl) in the HPLC system (Waters) using Chromolith C-18e column (Merck, 50 X 4.6 mm). The 
binary mobile phase consisted of A (water) and B (acetonitrile) was used. The isocratic elution was used 
as follows: 80 min run time with 90% acetonitrile and 10% water. The flow rate was 1 mL/minutes and 
the results were analyzed using UV-PDA detector. 
Synthesis of khellinone (2). The mixture of khellin (900 mg, 3.46 mmol) and potassium hydroxide (1 
M) in ethanol was refluxed at 90 °C over a period of 12-14 h. After completion of the reaction, ethanol 
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was evaporated over vacuo rotavapor and the obtained residue was partitioned in between 
dichloromethane and water. The dichloromethane layer was washed with brine solution and was dried 
over anhydrous sodium sulphate. The solvent was evaporated over vacuo rotavapor and the obtained 
crude product was purified using silica gel column chromatography (5-10% ethyl acetate in hexane) to 
get khellinone (2) as a yellow powder. The purchased khellin along with khellinone were characterized 
using spectral analysis. 
Khellin (1):  white crystals; HPLC: tR = 4.6 min (99% purity); m.p. 155-156 οC; IR (CHCl3): νmax 
3436, 3160, 3137, 2989, 2931, 2960, 2830, 1619, 1586, 1471, 1444, 1424, 1364, 1380, 1300, 1265 cm-1; 
1H NMR (400 MHz, CDCl3): δ (ppm) 7.51 (d, J = 2.2 Hz, 1H, CH), 6.91 (d, J = 4.0 Hz, 1H, CH ), 4.15 
(s, 3H, OMe), 4.05 (s, 3H, OMe), 2.73 (s, 3H, Me); 13C NMR (100 MHz, CDCl3): δ (ppm) 206.2 (C=O), 
153.5 (C-7a), 152.3 (C-6), 151.6 (C-3), 143.8 (OCH=CH), 128.8 (C-7), 110.8 (C-3a), 110.5 (C-5), 106.7 
(OCH=CH), 61.0 (OMe), 60.9 (OMe), 33.2 (Me); HR-ESIMS: m/z 237.0759 [M+H]+calcd  for  
C12H12O5 + H+(237.0757).25 
1-(6-Hydroxy-4,7-dimethoxy-benzofuran-5-yl) (2):  yellow crystals; HPLC: tR = 4.6 min (99% purity); 
yield: 61%; m.p. 169-170 οC; IR (CHCl3): νmax 3436, 3160, 3137, 2989, 2931, 2960, 2830, 1619, 1586, 
1471, 1444, 1424, 1364, 1380, 1300, 1265 cm-1; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.51 (d, J = 2.2 
Hz, 1H, CH), 6.91 (d, J = 4.0 Hz, 1H, CH), 4.15 (s, 3H, OMe), 4.05 (s, 3H, OMe), 2.73 (s, 3H, Me); 13C 
NMR (100 MHz, CDCl3): δ (ppm) 206.2 (C=O), 153.5 (C-7a), 152.3(C-6), 151.6 (C-3), 143.8 
(OCH=CH), 128.8 (C-7), 110.8 (C-3a), 110.5 (C-5), 106.7 (OCH=CH), 61.0 (OMe), 60.9 (OMe), 33.2 
(Me); HR-ESIMS: m/z 237.0759 [M+H]+ calcd  for  C12H12O5 + H+(237.0757).15 
Synthesis of furanochalcones 3a-v. Khellinone (80 mg, 0.338 mmol) was reacted with different 
aromatic aldehydes (1.2 equiv.) in the presence of catalytic amount of 1 M of KOH in 50 ml methanol at 
a temperature of 0 °C to 1 °C over a period of 12-14 h. After completion of the reaction, methanol was 
evaporated over vacuo rotavapor and the obtained residue was partitioned in between dichloromethane 
and water. The dichloromethane layer was washed with brine solution and was dried over anhydrous 
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sodium sulphate. The solvent was evaporated over vacuo rotavapor and the obtained crude product was 
purified using silica gel column chromatography (5-25%) to get furanochalcones 3a-v in 40-85% yield. 
 (1-(6-Hydroxy-4,7-dimethoxy-benzofuran-5-yl)-3-phenyl-propenone) (3a): yellow orange solid;  
HPLC: tR = 4.7 min (99% purity); yield: 41%; m.p. 123-126 οC; IR (CHCl3): νmax 3860, 3791, 3697, 
3436, 3060, 2930, 2850, 1630, 1606, 1559, 1494, 1446, 1360 cm-1;  1H NMR (400 MHz, CDCl3): δ  
(ppm) 7.88 (d,  J = 2.2 Hz, 2H, CH), 7.64-7.67 (m, 2H), 7.53 (d, J = 2.2 Hz, 1H, OCH=CH), 7.42-7.45 
(m, 3H), 6.89 (d, J = 4.0 Hz, 1H, OCH=CH), 4.09 (s, 3H, OMe), 4.05 (s, 3H, OMe); 13C NMR (100 
MHz, CDCl3): δ  (ppm) 194.7 (C=O), 153.2 (C-9a), 151.9 (C-6), 150.7 (C-4), 144.1(CH=CH), 143.5 
(OCH=CH), 135.1, 130.4, 129.6, 129.0, 128.5, 127.0, 112.8, 111.9, 105.2 (OCH=CH), 62.0, 61.0; HR-
ESIMS: m/z 325.1078 [M+H]+ calcd  for  C19H16O5 + H+ (325.1075).16 
3-(4-Bromo-phenyl)-1-(6-hydroxy-4,7-dimethoxy-benzofuran-5-yl)-popenone) (3b):  white solid; 
HPLC: tR = 4.5 min (100% purity); yield: 52%; m.p. 135-137 °C; IR (CHCl3): νmax  3400,     2919, 
2850, 1682, 1613, 1544, 1414, 1389, 1435, 1349, 1279, 112, 1012 cm-1;  1H NMR (400 MHz, CDCl3): δ  
(ppm) 7.82 (d, J = 12.0 Hz, 2H, CH), 7.58 (d, J = 8.0 Hz, 1H, CH), 7.53 (d, J = 4.0 Hz, 1H, OCH=CH), 
7.40 (d, J = 12.0 Hz, 2H, CH), 6.89 (d, J = 4.0 Hz, 1H, OCH=CH), 4.09 (s, 3H, OMe), 4.04 (s, 3H, 
OMe); 13C NMR (100 MHz, CDCl3): δ  (ppm) 194.4 (C=O), 153.1 (C-6), 152.1 (C-9a), 150.7 (C-4), 
144.3 (OCH=CH), 141.4, 137.3, 133.1, 130.9, 130.5, 127.2, 123.1, 112.7, 111.7, 106.2 (OCH=CH), 
62.0, 61.0; HR-ESIMS m/z 403.0175 [M+H]+ calcd for C19H15BrO5 + H+  (403.0175).   
3-(4-Chlorophenyl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one (3c): orange 
crystals; HPLC: tR = 49.6 min (90% purity); yield: 48%; m.p. 152-154 °C; IR (CHCl3): νmax 3448, 3053, 
2928, 2868, 2304, 1730, 1656, 1619, 1585, 1462, 1386, 1327, 1313, 12679, 1262, 1210, 1149, 1039 cm-
1; 1H NMR (400 MHz,  CDCl3): δ (ppm)  7.98 (d,  J = 4.0 Hz, 2H, CH), 7.52 (d, J = 4.0 Hz, 1H, 
OCH=CH), 7.40 (d, J = 8.0 Hz, 2H, CH), 7.19 (m, 2H, CH), 6.88 (d, J = 4.0 Hz, 1H, OCH=CH), 4.09 
(s, 3H, OMe), 4.05 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.5 (C=O), 153.2 (C-6), 
152.0 (C-9a), 150.7 (C-4), 144.2 (OCH=CH), 141.9, 136.3, 133.6, 129.6, 129.3, 127.5, 127.4  112.7, 
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111.8, 106.2 (OCH=CH), 62.0, 61.0; HR-ESIMS: m/z 359.0677 [M+H]+ calcd for  C19H15 ClO5  + H+ 
(359.0608).26 
 3-(3-Bromo-4-fluorophenyl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one) (3d): 
white solid; HPLC: tR = 5.0 min (97% purity); yield: 44%; m.p.186-188 °C; IR (CHCl3): νmax 3400, 
2921, 2850, 1630, 1557, 1494, 1463, 1442, 1417, 1382, 1359, 1332, 1299, 1269, 1151, 1091 cm-1; 1H 
NMR (400 MHz,  CDCl3):  δ (ppm) 7.85 (m, 1H, CH), 7.76 (d, J = 8.0 Hz, 2H, CH), 7.54 (t,  J = 4.0 
Hz, 2H, CH), 7.12 (t, J = 12.0 Hz, 1H, CH), 6.89 (d, J = 2.2 Hz, 1H, OCH=CH), 4.09 (s, 3H, OMe), 
4.05 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.5 (C=O), 165.3 (d, 1JCF = 251 Hz), 
162.8, 153.1, 151.9, 150.6, 144.2 (OCH=CH), 142.2, 131.4, 130.4 (d, 3JCF =  8.0 Hz), 130.3, 129.6, 
126.7, 116.2 (2JCF = 22.0 Hz),  112.8,  111.9, 106.1 (OCH=CH), 62.0, 61.0;  HR-ESIMS: m/z 423.0060 
[M+H]+calcd for C19H14 BrFO5+ H+ (423.0060). 
3-(4-Fluro-phenyl)-1-(6-hydroxy-4,7-dimethoxy-benzofuran-5-yl)-propenone (3e):  cream colored oil; 
HPLC: tR = 48.4 min (98% purity);  yield: 40%; m.p.129-130 °C; IR (CHCl3): νmax 3400, 2922, 2851, 
1628, 1601, 1556, 1544, 1510, 1461, 1443, 1413, 1360, 1297, 1299, 1266, 1151, 1091 cm-1;  1H NMR 
(400 MHz,  CDCl3): δ (ppm) 7.82 (s, 2H, CH), 7.64 (dd, J = 8.0, 5.5 Hz, 2H, CH), 7.53 (d, J = 2.2 Hz, 
1H, OCH=CH), 7.12 (t, J = 8.6 Hz, 2H, CH), 6.88 (d, J = 2.3 Hz, 1H, OCH=CH), 4.09 (s, 3H, OMe), 
4.05 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.5 (C=O), 165.0 (d, 1JCF = 251.2 Hz), 
163.0, 153.1, 151.9, 150.7,  144.2 (OCH=CH),  142.2, 131.4, 130.4 (d, 3JCF = 8.75 Hz), 126.7 (d, 4JCF = 
3.0 Hz), 116.2 (d, 2JCF = 22.5 Hz), 112.8, 111.8, 106.2 (OCH=CH), 62.0, 61.0; HR-ESIMS: m/z 
365.0838 [M+Na]+ calcd for C19H15FNaO5 (365.0801).27 
3-(2,4-Difluro-phenyl)-1-(6-hydroxy-4,7-dimethoxy-benzofuran-5-yl)-propenone) (3f): white solid; 
HPLC: tR = 42.4 min (98% purity); yield: 40%; m.p. 154-156°C; IR (CHCl3): νmax 3400, 2919, 2850, 
1633, 1618, 1588, 1562, 1542, 1464, 1438, 1412, 1377, 1357, 1286, 1211, 1153, 1119 cm-1; 1H NMR 
(400 MHz,  CDCl3): δ (ppm) 7.83 (d, J = 16.0 Hz, 1H, CH), 7.72 (d, J = 12.0 Hz, 1H, CH), 7.54 (d, J = 
2.2 Hz, 1H, OCH=CH), 7.14 (d, J = 4.0 Hz, 2H, CH), 6.89 (d, J = 4.0 Hz, 1H, CH),  6.86 (d, J = 4.0 Hz, 
1H, OCH=CH), 4.09 (s, 3H, OMe), 4.07 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.2 
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(C=O), 164.8, 162.0, 153.2, 152.2, 150.8, 144.3 (OCH=CH), 140.2, 138.5, 129.5, 112.5, 111.6, 111.0, 
110.9, 110.7, 105.4, 105.2 (OCH=CH), 61.9, 61.0; HR-ESIMS: m/z  361.0912 [M+H]+ calcd for 
C19H14F2,O5 + H+ (361.0882). 
1-(6-Hydroxy-4,7-dimethoxybenzofuran-5-yl)-3-(pyridin-3-yl)prop-2-en-1-one (3g): yellow orange 
crystals; HPLC: tR = 49.6 min (95%); yield: 85%; m.p. 112-114 °C; IR (CHCl3): 3400, 2919, 2850, 
1633, 1618, 1588, 1562, 1542, 1464, 1438, 1412, 1377, 1357, 1286, 1211, 1153, 1119 cm-1; 1H NMR 
(400 MHz,  CDCl3): δ (ppm)  8.88 (s, 1H, CH ), 8.63 (d, J = 4.0 Hz, 1H, CH), 7.94 (m, 2H, CH), 7.81 
(d, J = 16.0 Hz, 1H, CH), 7.54 (d, J = 2.3 Hz, 1H, OCH=CH ), 7.37 (dd, J = 8.0, 4.9 Hz, 1H, CH), 6.89 
(d, J = 2.3 Hz, 1H, OCH=CH), 4.09 (s, 3H, OMe), 4.06 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ 
(ppm) 194.2 (C=O), 153.2, 152.2, 150.9, 149.8, 144.3, 139.3, 134.8, 131.0, 128.9, 123.8, 112.5, 112.5, 
111.6, 111.5, 106.3, 61.8, 61.1; HR-ESIMS: m/z 326.1033 [M+H]+ calcd for C18H15NO5 + H+ 
(326.1023). 
1-(6-Hydroxy-4,7-dimethoxybenzofuran-5-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (3h):  yellow 
crystals; HPLC: tR = 5.3 min (100% purity); yield: 52%; m.p. 148-149 °C IR (CHCl3): νmax 3435, 2923, 
2851, 1630, 1606, 1564, 1543, 1456, 1438, 1422, 1404, 1358, 1306, 1293, 1250, 1153, 1119 cm-1; 1H 
NMR (400 MHz,  CDCl3):  δ (ppm) 7.84 (d, J = 16.0 Hz, 2H, CH), 7.62 (d, J = 4.0 Hz, 2H, CH), 7.53 
(d, J = 2.3 Hz, 1H, OCH=CH), 7.30 (d, J = 12.0 Hz, 1H, CH), 6.95 (d, J = 4.0 Hz, 2H, CH),  6.89 (d, J = 
12.0 Hz, 1H, CH), 6.88 (d, J = 4.0 Hz, 1H, OCH=CH),  4.09 (s, 3H, OMe), 4.04 (s, 3H, OMe), 3.87 (s, 
3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.6 (C=O), 161.7, 153.2, 151.7, 150.6, 144.1 
(OCH=CH), 143.8, 130.3, 127.8, 124.5, 114.5, 113.4, 112.9, 112.0, 105.1 (OCH=CH), 62.0, 61.0, 55.4; 
HR-ESIMS: m/z 355.1171  [M+H]+ calcd for C20H18O6 + H+  (354.1103).27 
3-(2,6-Dichlorophenyl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one (3i):  orange 
yellow crystals; HPLC: tR = 5.3 min (100% purity); yield: 57%; m.p. 298-299 °C;  IR (CHCl3): νmax 
3399, 3161, 3090, 2951, 2921, 2851, 1640, 1613, 1577, 1472, 1441, 1427, 1378, 1357, 1328, 1301, 
1275, 1242, 1213, 1185, 1145 cm-1; 1H NMR (400 MHz,  CDCl3): δ (ppm) 7.98  (d, J = 8.0 Hz, 2H, 
CH), 7.52  (d, J = 2.3 Hz, 1H, OCH=CH), 7.40  (d, J = 8.0 Hz, 2H, CH), 7.23 (d, J = 8.0 Hz, 1H, CH), 
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6.88 (d, J = 4.0 Hz, 1H, OCH=CH), 4.09 (s, 3H, OMe), 4.07 (s, 3H, OMe);  13C NMR (100 MHz, 
CDCl3): δ (ppm) 194.4 (C=O), 153.4, 152.2, 151.1, 143.9 (OCH=CH), 141.7, 136.3, 135.3, 134.7, 
132.6, 129.9, 129.3, 128.8, 112.3, 111.5, 105.3 (OCH=CH), 61.9 (OMe), 61.1 (OMe); HR-ESIMS: m/z 
393.0287 [M+H]+ calcd for C19H14Cl2,O5 + H+(393.0291). 
3-(5-Bromo-2-ethoxyphenyl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one (3j): 
orange powder; HPLC: tR = 5.1 min (100% purity); yield: 55%; m.p. 260-261 °C; IR (CHCl3): νmax 
3399, 3161, 3090, 2951, 2921, 2851, 1640, 1613, 1577, 1472, 1441, 1427, 1378, 1357,  1328 cm-1; 1H 
NMR (400 MHz,  CDCl3): δ (ppm) 8.12 (d, J = 16.0 Hz, 1H, CH), 7.90 (d, J = 16.0 Hz, 1H, CH), 7.73 
(d, J = 4.0 Hz, 1H, CH),  7.53 (d, J = 2.2 Hz, 1H, OCH=CH), 7.43 (d, J = 4.0 Hz, 1H, CH ), 6.88 (d, J = 
2.2 Hz, 1H, OCH=CH), 6.82 (d, J = 8.0 Hz, 1H, CH), 4.13 (m, 2H, CH2), 4.09 (s, 3H, OMe), 4.04 (s, 
3H, OMe), 1.50 (t, J = 7.0 Hz,  3H, Me); 13C NMR (100 MHz, CDCl3):  δ (ppm) 194.7 (C=O), 157.1, 
157.0, 153.2, 151.9, 150.8, 144.2 (OCH=CH), 137.2, 134.0, 130.9, 128.1, 126.1, 113.9, 112.8, 112.8, 
111.9, 106.2 (OCH=CH), 64.4, 62.0, 61.0, 14.7; HR-ESIMS: m/z 447.0433 [M+H]+calcd for 
C21H19BrO6 + H+ (447.0437). 
3-(2-Chlorophenyl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one (3k): yellow 
powder; HPLC: tR = 5.1 min (100% purity); yield: 55%; m.p. 150-151°C; IR (CHCl3): νmax3435, 2922, 
2851, 2650, 2342, 1693, 1628, 1591, 1571, 1469, 1439, 1408, 1363, 1316 cm-1; 1H NMR (400 MHz,  
CDCl3): δ (ppm)  8.23 (d, J = 16.0 Hz, 1H, CH), 7.86 (d, J = 8.0 Hz, 1H, CH), 7.74 (d,  J = 2.2 Hz, 1H, 
CH), 7.53 (d, J = 2.3 Hz, 1H, OCH=CH), 7.33 (dd, J = 2.3, 4.0 Hz, 2H, CH), 6.88 (d, J = 2.3 Hz, 1H, 
OCH=CH), 4.09 (s, 3H, OMe), 4.05 (s, 3H, OMe);13C NMR (100 MHz, CDCl3): δ (ppm) 194.4 (C=O), 
153.1, 152.1, 150.7, 144.3 (OCH=CH), 141.1, 137.3, 133.1, 130.9, 130.5, 129.5, 128.3, 127.2, 123.1, 
112.7, 111.7, 105.2, 62.0, 61.0; HR-ESIMS: m/z 359.0680 [M+H]+ calcd for C19H15ClO5 + H+ 
(359.0680).26 
3-(4,7-dimethoxy-6-hydroxybenzofuran-5-yl)-1-(2-3-dimethoxyphenyl)-3-oxopropene (3l):  HPLC: tR 
= 4.7 min (100% purity); yield: 57%; m.p. 260-262 °C; IR (CHCl3): νmax 3400, 2923, 2851, 1627, 1561, 
1511, 1463, 1439, 1383, 1360, 1301, 1264,  1064, 1022 cm-1; 1H NMR (400 MHz, CDCl3): δ (ppm) 7.83 
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(d, J = 16.0 Hz, 2H, CH), 7.53 (d, J = 4.0 Hz, 1H, OCH=CH), 7.25 (d, J = 2.2 Hz, 2H, CH), 7.16 (d, J = 
4.0 Hz, 1H, CH), 6.91 (d, J = 12.0 Hz,  1H, CH), 6.87 (d, J = 4.0 Hz, 1H, OCH=CH), 4.09 (s, 3H, 
OMe), 4.03 (s, 3H, OMe), 3.95 (s, 3H, OMe), 3.93 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 
195.6 (C=O), 163.8, 161.1, 154.0, 152.2, 151.3, 144.7, 140.3, 131.4, 130.2, 125.3, 125.2, 118.0, 113.6, 
112.9, 106.2, 105.8, 62.7, 61.7, 56.2, 56.2; HR-ESIMS: m/z  385.1278 [M+H]+calcd for C21H20O7+ 
H+(385.1281). 
3-(4,7-Dimethoxy-6-hydroxybenzofuran-5-yl)-1-(2-4-dimethoxyphenyl)-3-oxopropene (3m): colorless 
oil; HPLC: tR = 4.7 min (100% purity);  yield: 55%; m.p. 264-266 °C; IR (CHCl3): νmax 3400, 2923, 
2851, 1627, 1561, 1511, 1463, 1439, 1383, 1360, 1301, 1264,  1064, 1022 cm-1; 1H NMR (400 MHz,  
CDCl3): δ (ppm)  8.21 (d, J = 16.0 Hz, 1H, CH), 7.93 (d, J = 16.0 Hz, 1H, CH), 7.61 (d, J = 8.0 Hz, 1H, 
CH), 7.51 (d, J = 2.2 Hz, 1H, OCH=CH), 6.87 (s, 1H, CH), 6.53 (d, J = 4.0 Hz, 1H, OCH=CH),  6.48  
(s, 1H, CH), 4.09 (s, 3H, OMe),  3.91 (s, 3H, OMe), 3.87 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ 
(ppm) 194.9 (C=O), 163.2, 160.5, 153.3, 151.5, 150.6, 144.0, 139.6, 130.7, 129.4, 124.6, 117.3, 112.9, 
112.2, 105.5, 105.2, 98.4, 62.0, 61.0, 55.5, 55.5; HR-ESIMS: m/z 385.1276 [M+H]+ calcd for C21H20O7+ 
H+ (385.1281).26 
1-(6-Hydroxy-4,7-dimethoxybenzofuran-5-yl)-3-(perfluorophenyl)prop-2-en-1-one (3n): white solid; 
HPLC: tR = 5.0 min (92% purity);  yield: 50%; m.p. 112-114 °C;  IR (CHCl3): νmax 3400, 2924, 2853, 
1726, 1656, 1500, 1462, 1385, 1280, 1209, 1151, 1053, 1021 cm-1; 1H NMR (400 MHz,  CDCl3): δ 
(ppm)  8.12 (d, J = 16.0 Hz, 1H, CH), 7.81 (d, J = 16.0 Hz, 1H, CH), 7.53 (d, J = 4.0 Hz, 1H, 
OCH=CH), 6.91 (d, J = 4.0 Hz, 1H, OCH=CH), 4.17 (s, 3H, OMe),  4.11 (s, 3H, OMe); 13C NMR (100 
MHz, CDCl3): δ (ppm) 194.3 (C=O), 153.5, 152.2, 151.0, 144.9, 144.1 (OCH=CH), 133.0, 132.9, 129.3, 
127.2, 112.1, 111.3, 108.6, 105.1 (OCH=CH), 61.3, 61.0; HR-ESIMS: m/z 415.0603 [M+H]+ calcd for 
C19H11F5O5 + H+ (415.0599). 
1-(6-Hydroxy-4,7-dimethoxybenzofuran-5-yl)-3-(2,4,5-trimethoxyphenyl)prop-2-en-1-one (3o):  
reddish orange crystals; HPLC: tR = 8.7 min (100 % purity); yield: 50%; m.p. 131-133 °C; IR (CHCl3): 
νmax 3434, 2930, 2867, 1724, 1656, 1517, 1463, 1385, 1263, 1210, 1159, 1084, 1024 cm-1; 1H NMR 
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(400 MHz,  CDCl3): δ (ppm) 8.29 (d, J = 16.0 Hz, 1H, CH),  7.92 (d, J = 16.0 Hz, 1H, CH), 7.59 (s, 1H, 
OCH=CH), 7.22 (m, 1H, CH), 6.94 (s, OCH=CH, 1H), 6.60 (s, 1H, CH), 4.16-3.97 (m, 15H, OMe); 13C 
NMR: (100 MHz, CDCl3): δ (ppm) 194.7, 154.8, 153.2, 152.7, 151.5, 150.5, 144.0, 143.3, 139.3, 129.6, 
124.4, 115.7, 113.0, 112.2, 111.2, 105.1, 96.7, 62.0 (OMe), 61.0 (OMe), 56.5 (OMe), 56.3 (OMe), 56.1 
(OMe); HR-ESIMS: m/z 415.1390 [M+H]+ calcd for C22H21O8 + H+ (415.1390). 
3-(3-Bromo-4-methoxyphenyl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one (3p): 
orange crystals; HPLC: tR = 5.4 min (100% purity); yield: 52%; m.p. 261-263 °C; IR (CHCl3): νmax 
3454, 2927, 2866, 1730, 1654, 1590, 1464, 1386, 1365, 1326, 1312, 1279, 1102, 1084, 1048 cm -1; 1H 
NMR (400 MHz,  CDCl3): δ (ppm) 8.11 (d, J = 16.0 Hz, 1H, CH), 7.86 (d, J = 16.0 Hz, 1H, CH), 7.73 
(s, 1H, CH), 7.52 (s, 1H, CH), 6.88 (s, 1H, CH), 6.84 (d, J = 8.0 Hz, 1H, CH), 4.09 (s, 3H, OMe), 4.06 
(s, 3H, OMe), 3.91 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.8 (C=O), 157.7, 153.2, 
151.9, 150.7, 144.2, 137.1, 134.0, 134.0, 130.9, 128.3, 128.3, 126.1, 113.0, 112.7, 105.2, 62.0 (OMe), 
61.0 (OMe), 55.8; HR-ESIMS: m/z 432.0300 [M+H]+ calcd for C20H17BrO6 + H+ (432.0281).   
3-(Benzo[d][1,3]dioxol-5-yl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one (3q): 
orange crystals; HPLC: tR = 5.6 min (92% purity); yield: 53%; m.p. 248-251 °C;  IR (CHCl3): νmax 
3743, 3385, 3130, 2850, 1729, 1627, 1565, 1542, 1489, 1470, 1446, 1353, 1300, 1255 cm -1; 1H NMR 
(400 MHz,  CDCl3): δ (ppm) 7.78 (d, J = 16.0 Hz, 2H, CH), 7.53 (d, J = 4.0 Hz, 1H, OCH=CH), 7.15 
(m, 2H, CH), 6.88 (d, J = 2.2 Hz, 1H, OCH=CH), 6.87 (d, J = 8.0 Hz, 1H, CH), 6.04 (s, 2H, CH2), 4.09 
(s, 3H, OMe), 4.04 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.4 (C=O), 153.2, 151.7,  
150.6, 149.9,  148.4, 144.1,  143.8, 143.6, 129.6, 125.4, 124.9, 112.8, 111.9, 108.7, 106.6, 105.2, 101.6, 
62.0 (OMe), 61.0 (OMe);  HR-ESIMS: m/z 369.0968 [M+H]+calcd for C20H17O7 + H+ (369.0954).26 
1-(6-Hydroxy-4,7-dimethoxybenzofuran-5-yl)-3-(thiophen-3-yl)prop-2-en-1-one (3r): orange crystals; 
HPLC: tR = 3.9 min (85% purity); yield: 42%; m.p. 139-141 °C; IR (CHCl3): νmax 3584, 3136, 2922, 
2850, 1626, 1586, 1561, 1543, 1470, 1442, 1364, 1416, 1297,  1131 cm-1; 1H NMR (400 MHz,  CDCl3): 
δ (ppm) 7.89 (d, J = 16.0 Hz, 1H, CH),  7.73 (d, J = 16.0 Hz, 1H, CH),  7.62 (s, CH, 1H), 7.52 (s, 1H, 
CH), 7.40 (d, J = 8.0 Hz, 2H, CH),  6.87 (s, CH, 1H), 4.09 (s, 3H, OMe), 4.03 (s, 3H, OMe); 13C NMR 
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(100 MHz, CDCl3): δ (ppm) 194.8 (C=O), 153.1, 151.8, 150.6, 144.1, 138.5, 137.2, 129.6, 129.1, 127.0, 
126.6, 125.3, 112.8, 111.9, 105.1, 62.0 (OMe), 61.0 (OMe); HR-ESIMS: m/z 331.0619 [M+H]+ calcd 
for C17H15O5S+ H+ (331.0634). 
3-(2,4-Dichlorophenyl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-on (3s): orange 
crystals; HPLC: tR = 5.0 min (95% purity); yield: 42%;  m.p. 148-149 °C;  IR (CHCl3): νmax 3399, 3161, 
3090, 2951, 2921, 2851, 1640, 1613, 1577, 1472, 1441, 1427, 1378, 1357,  1328, 1301, 1275, 1242, 
1213, 1185, 1145 cm-1; 1H NMR (400 MHz,  CDCl3): δ (ppm) 8.14 (d, J = 16.0 Hz, 1H, CH), 7.83 (d,  J 
= 16.0 Hz, 1H, CH), 7.67 (d, J = 12.0 Hz, 1H, CH), 7.53 (d, J = 4.0 Hz, 1H, OCH=CH), 7.48 (d, J = 3.0 
Hz, 1H, CH),  7.31 (m, 1H, CH), 6.88 (d, J = 2.2 Hz, 1H, OCH=CH), 4.09 (s, 3H, OMe), 4.03 (s, 3H, 
OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.2 (C=O), 153.2, 152.1, 150.7, 144.3, 137.5, 136.3, 
136.1, 132.0, 130.1, 129.8, 129.5, 128.4,127.6, 112.6, 111.7, 105.2, 61.9, 61.0; HR-ESIMS: m/z 
393.0275 [M+H]+calcd for C19H14Cl2O5 + H+ (393.0291). 
1-(6-Hydroxy-4,7-dimethoxybenzofuran-5-yl)-3-(naphthalen-2-yl)prop-2-en-1-one (3t): orange 
crystals; HPLC: tR = 7.1 min (99% purity);  yield: 42%; m.p. 158-159 °C;  IR (CHCl3): νmax 3584, 3136, 
2922, 2850, 1626, 1586, 1561, 1543, 1470, 1442, 1379, 1297, 1149 cm-1; 1H NMR (400 MHz, CDCl3): 
δ (ppm) 8.03 (m, 3H, CH), 7.86 (m, 4H, CH), 7.54 (d, J = 2.2 Hz, 1H, OCH=CH), 7.53 (m, 3H, CH), 
6.90 (d, J = 2.2 Hz, 1H, OCH=CH), 4.10 (s, 3H, OMe), 4.07 (s, 3H, OMe); 13C NMR (100 MHz, 
CDCl3): δ (ppm) 194.6 (C=O), 153.5, 153.2, 150.7, 144.2, 143.7, 134.3, 133.4, 132.7, 130.7, 128.7, 
128.6, 127.8, 127.4, 127.1, 126.8, 123.7, 112.9, 112.0, 110.6, 105.2, 62.1, 60.5; HR-ESIMS: m/z 
375.1194 [M+H]+ calcd for C23H18O5 + H+ (375.1127).26 
3-(2-Fluorophenyl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one (3u): orange 
crystals; HPLC: tR = 5.0 min (95% purity); yield: 52%; m.p. 139-141 °C; IR (CHCl3): νmax 3400, 2922,  
2851, 1628, 1601, 1556, 1544, 1510, 1461,  1443,  1413, 1360, 1297,1299, 1266, 1151 cm-1; 1H NMR 
(400 MHz,  CDCl3): δ (ppm) 7.96 (q, J = 15.8 Hz, 2H, CH), 7.64 (t, J = 7.1 Hz, 1H, CH), 7.53 (d, J = 
2.2 Hz, 1H, OCH=CH,), 7.38 (m, 1H, CH), 7.17 (m, 2H, CH), 6.89 (d, J = 4.0 Hz, 1H, OCH=CH); 13C 
 26 
NMR (100 MHz, CDCl3): δ (ppm) 194.8 (C=O), 162.8 (d, 1JCF = 246 Hz), 160.7, 153.3, 152.1, 150.9, 
144.1, 136.0, 131.8 (d, 3JCF = 8.75 Hz),  129.8 (d, 4JCF = 3.7 Hz), 129.6 ( d, 3JCF = 6.0 Hz), 124.5 (d, 4JCF 
= 3.7 Hz), 123.3, 116.4 (d,  2JCF  = 21.2Hz), 112.5, 111.7, 105.3, 61.8, 61.0; HR-ESIMS: m/z 432.0300 
[M+H]+ calcd for C20H17BrO6 + H+ (432.0281).26 
3-(Anthracen-2-yl)-1-(6-hydroxy-4,7-dimethoxybenzofuran-5-yl)prop-2-en-1-one (3v): orange 
crystals; HPLC: tR = 7.4 min (100% purity); yield: 52%; m.p. 156-158 °C;  IR (CHCl3): νmax 3419, 
2920, 2850, 2103, 1632, 1569, 1442, 1408, 1359, 1215, 1146, 1065 cm-1; 1H NMR (400 MHz,  CDCl3): 
δ (ppm) 8.82 (d, J = 15.8 Hz, 1H, CH), 8.49 (s, 1H, CH), 8.40 (d, J = 8.4 Hz, 2H, CH),  8.05 (d, J = 7.4 
Hz, 2H, CH),  7.76 (d, J = 15.8 Hz, 1H, CH), 7.53 (m, 5H, CH), 6.87 (d, J = 2.2 Hz, 1H, OCH=CH), 
4.11 (s, 3H, OMe), 4.07 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 194.3 (C=O), 153.3, 
152.3, 150.9, 144.0, 140.2, 135.9, 131.3, 130.3, 129.7, 129.2, 128.9, 128.9, 128.4, 128.4, 128.3, 126.3, 
126.3, 125.4, 126.4, 111.7, 111.5, 105.5, 61.4, 61.1;  HR-ESIMS: m/z 425.1374 [M+H]+ calcd for 
C27H20O5 + H+ (425.1383). 
Synthesis of furanoflavonones 4a-p. Khellinone (100 mg, 0.423 mmol) was treated with different 
aldehydes (1.2 equiv.) in the presence of catalytic amount of piperidine in ethanol (2 ml) at 70 οC for 12 
hrs. The solvent was evaporated on rotary evaporator and the remaining mixture was diluted with water 
and dichloromethane. The organic layer was separated, dried over anhydrous sodium sulphate and 
concentrated to dryness on rotary evaporator. The obtained crude product was purified using silica gel 
column chromatography (5-40%) to yield furanoflavonones 4a-p in 51-68% yield. 
4,9-Dimethoxy-7-phenyl-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4a): yellow powder;  HPLC: tR 
= 4.1 min (100% purity); yield: 65%; m.p. 148-150 °C;  IR (CHCl3): νmax 3444, 3021, 2932, 2851, 2347, 
2072, 1682, 1614, 1542, 1477, 1435, 1351, 1278, 1163, 1066, 1029 cm-1; 1H NMR (400 MHz, CDCl3): 
δ  (ppm) 7.52 (d, J = 2.2 Hz, 1H, OCH=CH), 7.50 (m, 2H, CH ), 6.93 (d, J = 2.2 Hz, 1H, OCH=CH), 
5.49 (dd, J = 12.3, 3.0 Hz, 1H, CH), 4.08 (s, 3H, OMe), 4.06 (s, 3H, OMe),  3.09 (dd, J = 16.7, 12.4 Hz, 
1H), 2.94 (dd, J = 16.7, 3.1 Hz, 1H ); 13C NMR (100 MHz, CDCl3): δ (ppm) 190.7 (C=O), 152.0 (C-9a), 
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151.4 (C-4), 150.0 (C-8a), 144.4 (OCH=CH), 138.8 (C-1'), 130.0 (C-9), 128.8 (Ar-3', Ar-5'), 128.5 (Ar-
4), 126.0 (Ar-2', Ar-6'), 115.6 (C-4a), 111.4 (C-3a), 105.6 (OCH=CH), 79.3 (C-7), 61.5 (OMe), 61.4 
(OMe), 46.1 (C-6);  HR-ESIMS: m/z 325.1072 [M+H]+ calcd  for  C19H16O5 + H+ (325.1070). 
7-(2-Bromophenyl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4b): yellow powder; 
HPLC: tR = 4.3 min (100% purity); yield: 63%; m.p. 146-148 °C;  IR (CHCl3): νmax 3708, 3418, 2922, 
2850, 2400, 2095, 1659, 1644, 1477, 1435, 1349, 1302 cm-1;  1H NMR (400 MHz, CDCl3): δ  (ppm) 
7.68 (d, J = 1.4 Hz, 1H, CH),  7.53 (d, J = 2.3 Hz, 1H, OCH=CH), 7.51 (m, 1H, CH),  7.42 (d, J = 7.8 
Hz, 1H, CH), 7.29 (d, J = 8.0 Hz, 1H, CH),  6.94 (d, J = 2.3 Hz, 1H,OCH=CH), 5.45 (dd, J = 12.2, 3.2 
Hz, 1H, CH), 4.08 (s, 3H, OMe), 4.06 (s, 3H, OMe), 3.04 (dd, J = 12.2, 1.3 Hz, 1H), 2.94 (dd, J = 6.7, 
3.3 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ (ppm) 190.7 (C=O), 152.0 (C-9a), 151.0 (C-4), 150.0 (C-
8a), 144.5 (OCH=CH),  141.0 (C-1'), 131.7 (C-3'), 130.4 (C-4'),  130.0 (C-9), 129.1 (C-5'), 124.6 ( C-
6'), 122.9 (C-2'), 115.7 (C-4a), 111.2 (C-3a), 106.7 (OCH=CH), 78.4 (C-7),  61.4 (OMe), 61.4 (OMe), 
46.0 (C-6); HR-ESIMS: m/z 403.0170 [M+H]+calcd  for  C19H15BrO5 + H+(403.1750). 
7-(Benzo[d][1,3]dioxol-5-yl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4c):  yellow 
powder; HPLC: tR = 3.5 min (100% purity); yield: 60%; m.p. 150-154 °C; IR (CHCl3): νmax 3743, 3584, 
3415, 2922, 2850, 1681, 1614, 1542, 1504, 1491, 1477, 1445, 1390, 1349, 1300, 1277 cm-1;  1H NMR 
(400 MHz, CDCl3): δ  (ppm) 7.52 (d, J = 2.2 Hz, 1H, OCH=CH),  7.02 (d, J = 1.4 Hz, 1H, CH), 6.94  
(d, J = 2.3 Hz, 1H, OCH=CH), 5.99 (s, 2H, CH2),  5.39 (dd, J = 12.2, 3.2 Hz, 1H, CH),  4.07 (s, 3H, 
OMe), 4.04 (s, 3H, OMe),  3.06 (dd, J = 16.7, 12.3 Hz, 1H), 2.89 (dd, J = 16.7, 3.1 Hz, 1H);  13C NMR 
(100 MHz, CDCl3): δ (ppm) 190.7 (C=O), 152.0 (C-9a), 151.3 (C-4), 150.0 (C-8a), 148.0 (C-3'), 147.8 
(C-4'), 144.4 (OCH=CH), 132.6 (C-9),  129.9 (C-1'), 119.9 (C-6'), 115.5 (C-4a), 111.2 (C-3a), 108.3 (C-
5'), 106 (C-2'), 105.6 (OCH=CH),  101.3 (CH2), 79.2 (C-7),  61.5 (OMe), 61.4 (OMe), 46.1 (C-6); HR-
ESIMS: m/z 369.0968 [M+H]+ calcd  for  C20H16O7 + H+(369.0968). 
7-(5-Bromo-2-methoxyphenyl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4d):  
yellow powder; HPLC: tR = 4.4 min (100% purity); yield: 66%; m.p. 178-180 °C;  IR (CHCl3): νmax 
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3743, 3584, 3415, 2922, 2850, 1681, 1614, 1542, 1504, 1491, 1477, 1445, 1390, 1349, 1300, 1277 cm-1;  
1H NMR (400 MHz, CDCl3): δ (ppm) 7.79 (d, J = 2.0 Hz, 1H, CH), 7.53 (d, J = 2.3 Hz, 1H, OCH=CH),  
7.43 (dd, J = 8.7, 2.5 Hz, 1H, CH), 6.94  (d, J = 2.3 Hz, 1H, OCH=CH), 6.79 (d, J = 8.8 Hz, 1H, CH),  
5.73 (dd, J = 12.9, 2.7 Hz, 1H, CH),  4.09 (s, 3H, OMe), 4.07 (s, 3H, OMe), 3.82 (OMe), 2.99 (dd, J = 
16.8, 2.9 Hz, 1H), 2.83 (dd, J = 16.8, 12.9 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ (ppm)  190.8 
(C=O), 154.8 (C-2'), 151.9 (C-9a), 151.6 (C-4), 150.1 (C-8a), 144.4 (OCH=CH), 131.8 (C-4'),  130.1 
(C-9), 129.8 (C-1'), 129.6 (C-6'), 115.8 (C-4a), 113.3 (C-3a), 112.2 (C-3'), 111.4 (C-5'), 105.6 
(OCH=CH), 74.2 (C-7), 61.5 (OMe), 61.4 (OMe), 45.1 (C-6); HR-ESIMS: m/z 433.0274 [M+H]+ calcd  
for  C20H17O7 + H+ (433.0281). 
4,9-Dimethoxy-7-(pyridin-3-yl)-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4e): yellow powder;  
HPLC: tR = 3.3 min (100% purity); yield: 65%; m.p. 149-151 °C; IR (CHCl3): νmax  3584, 3380, 3124, 
3074, 2937, 2850, 1668, 1599, 1479, 1547, 1437, 1344, 1392, 1285, 1078 cm-1;  1H NMR (400 MHz, 
CDCl3): δ  (ppm) 8.78  (s, 1H, CH), 8.65 (d, J = 4.6 Hz, 1H, CH), 7.86 (d, J = 7.9 Hz, 1H, CH),  7.54 (d, 
J = 2.1 Hz, 1H,OCH=CH),  7.38 (dd, J =7.8, 4.8 Hz, 1H, CH), 6.95  (d, J = 2.1 Hz, 1H, OCH=CH),  
5.54 (dd, J = 12.3, 3.1 Hz, 1H, CH),  4.09 (s, 3H, OMe), 4.06 (s, 3H, OMe),  3.10 (dd, J =16.6, 12.4 Hz, 
1H), 2.97  (dd, J =16.7, 3.2 Hz, 1H) ; 13C NMR (100 MHz, CDCl3): δ (ppm) 190.8 (C=O), 152.0 (C-9a), 
150.9 (C-4), 150.1 (C-8a), 150.0 (C-6'), 147.8 (C-4'), 144.5 (OCH=CH), 134.3 (C-9), 133.6 (C-2'), 
130.0 (C-1'), 123.6 (C-3'), 115.8 (C-4a), 111.2 (C-3a), 106.6 (OCH=CH), 77.3 (C-7), 61.4 (OMe), 61.3 
(OMe), 45.6 (C-6); HR-ESIMS: m/z 326.1021 [M+H]+ calcd  for  C18H16 NO5 + H+ (325.1023). 
4,9-Dimethoxy-7-(thiophen-3-yl)-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4f):  yellow powder; 
HPLC: tR = 5.3 min (89% purity); yield: 66%; m.p. 159-161 °C; IR (CHCl3): νmax  3428, 1927, 2851, 
2079, 1673, 1651, 1620, 1477, 1542, 1435, 1348, 1300, 1216 cm-1;  1H NMR (400 MHz, CDCl3): δ  
(ppm) 7.52 (d, J = 2.2 Hz, 1H, OCH=CH), 7.37 (m, 2H, CH),  7.21 (dd, J = 4.9, 1.3 Hz, 1H, CH), 6.92  
(d, J = 2.3 Hz, 1H, OCH=CH),  5.60 (dd, J = 10.3, 4.1 Hz, 1H, CH),  4.07 (s, 3H, OMe), 4.06 (s, 3H, 
OMe),  3.12 (dd, J = 16.7, 10.3 Hz, 1H), 3.04 (dd, J = 16.7, 4.1 Hz, 1H); 13C NMR (100 MHz, CDCl3): 
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δ (ppm) 190.5 (C=O), 152.0 (C-9a), 151.0 (C-4), 150.0 (C-8a), 144.4 (OCH=CH), 139.8 (C-1'), 128.8 
(C-9), 126.7 (C-3'), 125.8 (C-2'), 122.6 (C-5'), 115.5 (C-4a), 111.4 (C-3a), 106.7 (OCH=CH), 75.4 (C-
7),  61.4 (OMe), 61.4 (OMe), 45.1 (C-6); HR-ESIMS: m/z 331.0643 [M+H]+ calcd  for  C17H14 O5S+ H+ 
(331.0634). 
4,9-Dimethoxy-7-(4-nitrophenyl)-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4g):  yellow powder; 
HPLC: tR = 3.6 min (100% purity); yield: 61%; m.p. 180-181 °C; IR (CHCl3): νmax  3745, 3383, 2850, 
2918, 1734, 1702, 1604, 1519, 1503, 1467, 1345, 1273, 1213, 1149, 1066  cm-1;  1H NMR (400 MHz, 
CDCl3): δ (ppm) 8.10 (d, J = 8.7 Hz, 2H,CH), 7.56-7.49 (dd, J = 7.6, 5.5 Hz, 2H, CH), 6.91 (d, J = 2.3 
Hz, 1H, OCH=CH), 4.88 (dd, J = 6.5, 4.4 Hz, 1H, CH), 4.12 (s, 3H, OMe), 4.06 (s, 3H, OMe),  3.47 
(dd, J = 16.2, 4.0 Hz, 1H), 3.04  (dd, J = 14.6, 6.6 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ (ppm) 196.5 
(C=O), 159.6 (C-9a), 154.7 (C-4), 147.1 (C-1'), 146.9 (C-4'), 144.5 (OCH=CH), 143.1 (C-8a), 130.6 (C-
2', C-6'), 127.7 (C-9), 123.5 (C-3', C-5'), 113.8 (C-4a), 108.3 (C-3a), 106.1 (OCH=CH), 85.4 (C-7),  
61.2 (OMe), 60.8 (OMe), 37.1 (C-6); HR-ESIMS: m/z 370.0933 [M+H]+ calcd  for  C19H15 NO7+ H+ 
(370.0931). 
7-(2-Chlorophenyl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one  (4h): yellow powder; 
HPLC: tR = 4.4 min (100% purity); yield: 65%; m.p. 142-143 °C;  IR (CHCl3): νmax  3625, 3584, 3441, 
2934, 2849, 2079, 1682, 1651, 1542,  1435,  1391, 1303, 1278 cm-1;  1H NMR (400 MHz, CDCl3): δ  
(ppm) 7.67 (t, J = 7.3 Hz, 1H, CH), 7.54 (d, J = 2.1 Hz, 1H, OCH=CH), 7.40-7.34 (m, 1H, CH), 7.25 
(dd, J = 12.2, 4.4 Hz, 1H, CH), 7.15-7.08 (m, 1H, CH), 6.95  (d, J = 2.1 Hz, 1H, OCH=CH),  5.77 (dd, J 
=12.5, 3.0 Hz, 1H),  4.12 (s, 3H, OMe), 4.06 (s, 3H, OMe),  3.07 (dd, J = 16.7, 12.6 Hz, 1H), 2.96 (dd, J 
= 16.8, 3.2 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ (ppm) 190.3 (C=O), 152.0 (C-9a), 151.4 (C-4), 
150.2 (C-8a), 144.5 (OCH=CH), 136.7 (C-1'), 131.7 (C-2'), 130.0 (C-9), 129.7 (C-3'), 129.5 (C-4'), 
127.4 (C-6'), 127.1 (C-5'), 115.7 (C-4a), 111.3 (C-3a), 105.7 (OCH=CH), 77.5 (C-7), 61.5 (OMe), 61.5 
(OMe), 44.9 (C-6); HR-ESIMS: m/z  359.0670 [M+H]+ calcd  for  C19H15 ClO5+ H+(359.0675). 
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(2,4-Dichlorophenyl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one  (4i): yellow powder; 
HPLC: tR = 4.5 min (100% purity); yield: 64%; m.p. 123-125 °C; IR (CHCl3): νmax 3584, 3354, 3019, 
2930, 2850, 1683, 1614, 1543, 1479, 1485, 1348, 1278, 1165, 1130, 1102, 1018 cm-1;  1H NMR (400 
MHz, CDCl3): δ (ppm) 7.79 (d, J = 8.4 Hz, 1H, CH), 7.55 (d, J = 2.1 Hz, 1H, OCH=CH), 7.44 (m, 1H, 
CH), 7.38 (dd, J = 8.4, 2.1 Hz, 1H, CH),  6.96  (d, J = 2.3 Hz, 1H, OCH=CH), 5.78 (dd, J = 13.0, 2.8 
Hz, 1H, CH), 4.11 (s, 3H, OMe), 4.05 (s, 3H, OMe), 3.03 (dd, J = 16.8, 2.9 Hz, 1H), 2.86 (dd, J = 16.8, 
13.0 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ (ppm) 189.9 (C=O), 152.0 (C-9a), 151.1 (C-4), 150.2 (C-
8a), 144.6 (OCH=CH),  135.3 (C-9),  134.8 (C-1'), 132.3 (C-4'), 130.1 (C-2'), 129.5 (C-3'), 128.1 (C-6'), 
127.8 (C-5'), 115.8 (C-4a), 111.1 (C-3a), 105.7 (OCH=CH), 76.0 (C-7),  61.5 (OMe), 61.5 (OMe), 44.8 
(C-6); HR-ESIMS: m/z  393.0282 [M+H]+ calcd  for  C19H15 Cl2O5+ H+ (393.0291). 
4,9-Dimethoxy-7-(naphthalen-2-yl)-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4j):  yellow powder; 
HPLC: tR = 5.2 min (100% purity); yield: 60%; m.p. 143-145 °C; IR (CHCl3): νmax 3418, 2925, 2852, 
2085, 1680, 1616, 1545, 1497, 1436, 1390, 1302, 1249, 1126, 1018 cm-1; 1H NMR (400 MHz, CDCl3): 
δ (ppm) 7.79 (m, 4H, CH), 7.63 (d, J = 8.5 Hz. 1H, OCH=CH), 7.52 (m, 3H, CH), 6.94 (d, J = 2.2 Hz, 
1H, OCH=CH),  5.66  (dd, J = 16.7, 12.2 Hz, 1H, CH), 4.09 (s, 3H, OMe), 4.07 (s, 3H, OMe), 3.20  (dd, 
J = 16.7, 12.2 Hz, 1H), 3.04 (dd, J  = 16.7, 3.1 Hz, 1H); 13C NMR (100 MHz, CDCl3): δ (ppm) 190.7 
(C=O), 152.1 (C-9a), 151.4 (C-4), 150.1 (C-8a), 144.4 (OCH=CH), 136.1 (C-9), 133.8 (C-8'), 133.1 (C-
3'), 130.0 (C-1'), 128.7 (C-9'), 128.2 (C-10'), 127.7 (C-4', C-7'), 115.6 (C-3a), 111.4 (C-4a), 106.7 
(OCH=CH), 79.4 (C-7),  61.5 (OMe), 61.4 (OMe), 46.0 (C-6), HR-ESIMS: m/z  375.1230 [M+H]+ calcd  
for  C23H18 O5+ H+ (375.1227). 
7-(2,6-Dichlorophenyl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4k): yellow 
powder; HPLC: tR = 4.4 min (100% purity); yield: 65%; m.p. 143-145 °C;  IR (CHCl3): νmax  3444, 
3011,  2936,  2848,  2111, 1682, 1614, 1581, 1564, 1477, 1434, 1376, 1348, 1277, 1247, 1211 cm-1;  1H 
NMR (400 MHz, CDCl3): δ (ppm) 7.53 (d, J = 2.2 Hz, 1H, OCH=CH), 7.39 (d, J = 8.0 Hz, 2H, CH), 
7.28 (m, 1H, CH), 6.95 (d, J = 2.2 Hz, 1H, OCH=CH),  6.25 ( dd, J = 14.4, 3.1 Hz, 1H, CH),  4.11 (s, 
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3H, OMe), 4.03 (s, 3H, OMe),  3.77 (dd, J = 16.8, 14.5Hz, 1H), 2.69 (dd, J = 16.8, 3.1 Hz, 1H) ; 13C 
NMR (100 MHz, CDCl3): δ (ppm) 190.1 (C=O), 152.3 (C-9a), 151.5 (C-4), 150.3 (C-8a), 144.5 
(OCH=CH), 135.1 (C-9), 134.8 (C-1'),132.5 (C-2', C-6'), 130.2 (C-3'), 129.7 (C-4'), 128.9 (C-5'), 115.4 
(C-3a), 111.0 (C-4a), 105.7 (OCH=CH), 75.9 (C-7),  61.9 (OMe), 61.5 (OMe), 41.0 (C-6); HR-ESIMS: 
m/z  393.0331 [M+H]+ calcd  for  C19H14 Cl2O5+ H+ (393.0291). 
7-(3-Bromo-4-fluorophenyl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one  (4l):  yellow 
powder; HPLC: tR = 4.1 min (95% purity); yield: 68%; m.p. 140-143 °C; IR (CHCl3): νmax  3429, 2933, 
2850, 2091, 1681, 1614, 1544, 1498, 1478, 1435, 1417, 1391, 1349, 1278, 1249, 1067 cm-1; 1H NMR 
(400 MHz, CDCl3): δ  (ppm)  7.73 (dd, J = 6.4, 2.0 Hz, 1H, CH), 7.54 (d, J = 2.2 Hz, 1H, OCH=CH), 
7.44-7.39 (m, 1H, CH), 7.18 (t,  J = 8.4 Hz, 1H, CH),  6.95 (d, J = 2.2 Hz, 1H, OCH=CH),  5.43 (dd, J = 
12.1, 3.1 Hz, 1H, CH),  4.08 (s, 3H, OMe), 4.06 (s, 3H, OMe),  3.03 (dd, J = 16.7, 12.1 Hz, 1H), 2.92 
(dd, J = 16.7, 3.3 Hz, 1H); 13C NMR (125 MHz, CDCl3): δ (ppm) 189.9 (C=O),  160.0 (d, 1JCF = 246 
Hz, C-4'), 158.0 (C-9a), 152.4 (C-4), 150.8 (C-8a), 150.1 (C-9) 144.6 (OCH=CH), 136.2 (d, 4JCF = 3.7 
Hz, CH-1'), 131.4 (C-2'), 129.9 (C-3a), 126.8 (d, 3JCF = 7.2 Hz, CH-6'), 116.9 (CH-5'), 111.1 (C-4a), 
109.6 (d, 2JCF = 21.2 Hz, C-3'), 106.7 (OCH=CH), 77.9 (C-7),  61.4 (OMe), 61.4 (OMe), 45.9 (C-6); 
HR-ESIMS: m/z  423.0060 [M+H]+ calcd  for  C19H14BrFO5+ H+ (423.0060). 
7-(2-Fluorophenyl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4m):  yellow powder; 
HPLC: tR = 3.7 min (93% purity); yield: 64%; m.p. 142-145 °C; IR (CHCl3): νmax 3584, 3360, 3126, 
3070, 2938, 2843, 1687, 1682, 1615, 1543, 1505,  1478, 1459, 1436, 1349, 1302, 1278, 1252, 1233, 
1165, 1130, 1067 cm-1; 1H NMR (400 MHz, CDCl3): δ (ppm)  7.67 (t, J = 7.3 Hz, 1H, CH), 7.54 (d, J  = 
2.1 Hz, 1H, OCH=CH), 7.37 (dd, J  = 13.3, 6.0 Hz, 1H, CH), 7.25 (dd, 1H, J  = 12.2, 4.4 Hz, CH), 7.15-
7.08 (m, 1H, CH),  6.95 (d, J  = 2.1Hz, 1H, OCH=CH),  5.77 (dd, J  = 12.5, 3.0 Hz, 1H, CH),  4.10 (s, 
3H, OMe), 4.05 (s, 3H, OMe), 3.07 (dd, J = 16.7, 12.6 Hz, 1H), 2.96 (dd, J = 16.8, 3.2 Hz, 1H); 13C 
NMR (125 MHz, CDCl3): δ (ppm) 190.4 (C=O), 160.7 (d, 1JCF = 246 Hz, C-2'),  158.7 (C-9a), 152.1 (C-
4), 151.4 (C-8a),  150.2 (C-9), 144.5 (OCH=CH), 130.2 (d,  3JCF = 8.7 Hz, CH-4'), 130.0 (C-3a), 127.4 
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(CH-6'),  126.2 (CH-1'), 124.6  (d, 4JCF = 3.7 Hz CH-5'), 115.8 (d,  2JCF  = 21.2 Hz, CH-3'), 111.1 (C-
4a), 105.7 (OCH=CH), 73.8 (CH-7),  61.5 (OMe), 61.5 (OMe), 45.1 (C-6);  HR-ESIMS: m/z  343.0990 
[M+H]+ calcd  for  C19H15FO5+ H+ (343.0976). 
7-(4-Fluorophenyl)-4,9-dimethoxy-6,7-dihydro-5H-furo[3,2-g]chromen-5-one  (4n):  yellow powder;  
HPLC: tR = 4.4 min (100% purity); yield: 61%; m.p. 142-145 °C; IR (CHCl3): νmax  3744, 3397, 2920, 
2351, 1683, 1575, 1512, 1477, 1414, 1348, 1301, 1226, 1126, 1065 cm-1; 1HNMR (400 MHz, CDCl3): δ 
(ppm) 7.53 (d, J = 2.2 Hz, 1H, OCH=CH), 7.49 (dd, J = 8.5, 5.4 Hz, 2H, CH), 7.12 (t,  J = 8.6 Hz, 1H, 
CH),  6.94 (d, J = 2.2 Hz, 1H, OCH=CH),  5.47 (dd, J = 12.3, 2.9 Hz, 1H, CH),  4.09 (s, 3H, OMe), 4.05 
(s, 3H, OMe),  3.07 (dd, J = 16.7, 12.3 Hz, 1H), 2.93 (dd, J = 16.7, 3.2 Hz, 1H ); 13C NMR (125 MHz, 
CDCl3): δ (ppm) 190.5 (C=O),  163.7 (d, 1JCF = 246 Hz , C-4'), 161.7 (C-9a), 152.0 (C-4), 151.2 (C-8a), 
150.0 (C-9), 144.5 (OCH=CH), 134.6 (CH-1'), 127.9 (d, 3JCF = 8.7 Hz, C-2', C-6'),  115.8 (d, 2JCF = 20.0 
Hz, C-3', C-5'), 115.6 (C-3a), 111.2 (C-4a), 105.6 (OCH=CH), 78.6 (C-7),  61.4  (OMe), 61.4 (OMe), 
45.9 (C-6); HR-ESIMS: m/z  343.0990 [M+H]+ calcd  for  C19H15FO5+H+ (343.0976).  
(E)-6-Benzylidene-4,9-dimethoxy-7-phenyl-6,7-dihydro-5H-furo[3,2-g]chromen-5-one (4o):  yellow 
powder; HPLC: tR = 3.7 min (87% purity); yield: 51%; m.p. 159-161 °C ; IR (CHCl3): νmax 3585, 3415, 
2922, 2850, 2094, 1641, 1619, 1475, 1437, 1348, 1277, 1126,  cm-1; 1H NMR (400 MHz, CDCl3): δ 
(ppm) 8.09 (s, 1H, CH), 7.98 (d, J = 2.1 Hz, 1H, CH), 7.50 (m, 5H, CH), 7.44 (t, J = 6.9 Hz, 4H), 7.38 
(d, J = 7.1 Hz, 1H, CH), 7.18 (d, J = 2.1 Hz, 1H, CH), 6.76 (s, 1H, CH), 4.00 (s, 3H, OMe), 3.94 (s, 3H, 
OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 180.0, 151.2, 149.8, 147.6, 145.4, 138.0, 137.1, 133.3, 
132.5, 130.1, 129.9, 129.8, 129.0, 128.9, 127.2, 115.3, 111.7, 105.7, 77.2, 61.1, 60.8; HR-ESIMS: m/z  
413.1383 [M+H]+ calcd  for  C26H20O5+ H+ (413.1383). 
(Z)-4,9-Dimethoxy-6-(thiophen-2-ylmethylene)-7-(thiophen-3-yl)-6,7-dihydro-5H-furo[3,2-
g]chromen-5-one  (4p): yellow powder; HPLC: tR = 4.6 min (95% purity); yield: 55%; m.p. 148-150 
°C; IR (CHCl3): νmax  3429, 2933, 2850, 2091, 1681, 1614, 1544, 1498, 1478, 1435, 1417, 1391, 1349, 
1278, 1249, 1067  cm-1; 1H NMR (400 MHz, CDCl3): δ  (ppm) 7.94-7.91 (m, 2H, CH),  7.86 (d,  J = 1.9 
 33 
Hz, 1H, CH), 7.67 (dd,  J = 4.9, 2.9 Hz, 1H, CH),  7.53 (d, J = 2.9 Hz, 1H, OCH=CH), 7.38-7.34 (m, 
1H, CH), 7.24 (d, J = 5.0 Hz, 1H, CH), 7.18 (d, J = 5.0 Hz, 1H, CH), 7.13 (d, J = 2.2 Hz, 1H, 1H), 6.83 
(s, 1H, CH), 3.96 (s, 3H, OMe), 3.86 (s, 3H, OMe); 13C NMR (100 MHz, CDCl3): δ (ppm) 180.8 
(C=O), 151.6, 150.2, 148.4, 144.1, 139.1, 135.8, 132.1, 131.0, 130.8, 129.1, 128.6, 127.0, 126.8, 126.7, 
124.7, 116.5, 112.7, 105.5, 75.1, 61.5, 61.4; HR-ESIMS: m/z  425.0495 [M+H]+ calcd  for  C22H16O5S2+ 
H+ (425.0511). 
CYP screening and protection from B[a]P toxicity. The activity of test compounds for inhibition of 
CYP enzymes was investigated using Sacchrosomes™ and recombinant human HEK293 cells using 
protocols, as described in our earlier publications.10, 12 The protection from B[a]P toxicity in CYP1A1-
expressing normal adherent HEK293 human cells was studied as per protocols described in our earlier 
publications.10, 12 
For IC50 determination for CYP inhibition, the enzyme inhibition was plotted using sigmoidal curve 
(4 parameter variable slope equation) and half-inhibitory concentration (IC50) values were analyzed 
statistically using GraphPad Prism Software (Version 6.0). The IC50 values of CYP inhibitors were 
determined by fitting a non-linear curve of uninhibited fraction with incubation concentration of the 
inhibitors, using the Hill equation. The EC50 values for B[a]P toxicity were determined by plotting dose-
response curve of cell viability versus log concentration of B[a]P or B[a]P + test compound. EC50 values 
were obtained using GraphPad Prism Software (Version 6.0), indicating the concentration of B[a]P 
required for 50% reduction in cell viability. 
Profiling of khellinochalcones on a panel of 12 humanized CYP450 enzymes. IC50 values of 
furanochalcone 3g were obtained by kinetic microplate assay using 15 minutes reaction time. 
Recombinant human P450s from a Saccharomyces cerevisiae microsome expression system supplied 
from CYP Design was used. Each 100 µl reaction was performed in 100 mM potassium phosphate 
buffer, pH 7.4 and with a NADPH regenerating system (final well concentrations 0.04 units of glucose-
6-phosphate dehydrogenase, 1.3 mM NADP+, 3.3 mM glucose-6-phosphate, 3.3 mM MgCl2 and 50 µM 
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tribasic sodium citrate). Test samples were serially diluted in 10% DMSO in decreasing final well 
concentrations from 20 µM downwards/ 0.5 % DMSO. CYP2E1 is sensitive to solvents and so test 
samples were diluted in 1% DMSO in decreasing final well concentrations from 10 µM downwards/ 0.5 
% DMSO. The assay was initiated by adding substrate and the NADPH regenerating system. P450 
content and substrate concentrations were pre-optimised.12  
In vitro cell proliferation assays and flow cytometric analyses. They were performed as 
described earlier.28 Control cells (i.e. in the absence of any compound) and cells (i.e. treated with 
compound) cells were harvested after treatment with trypsin. Cells were fixed in chilled (-20ºC) 70% 
ethanol for an hour, after washing once with PBS. Fixed cells were centrifuged at room temperature. 
Pellets were re-suspended in PBS, in the presence of DNase-free ribonuclease (0.5 mg/mL; Sigma-
Aldrich # R-5503) before staining with a propidium iodide solution (50 μg/mL; Sigma-Aldrich, # P-
4170) for an hour (in the dark) at 4 °C. Cell cycle analysis was performed on the Beckman Coulter 
(Epics Altra) fluorescence-activated cell sorter (Beckman Coulter UK Ltd). To exclude cell doublets or 
cell clumps, all events that represent single cells were gated. Cytograms of the fluorescence peak of 
propidium iodide were plotted against the integrated fluorescence/linear signal. Data points on a straight 
line, within a single gate, were isolated and the gated data was employed for plotting a histogram that 
represents a complete cell cycle. The total number of events did not exceed 200 events per second. Data 
acquisition was stopped after collection of around 10,000 events. 
In silico docking with CYP1A1. The docking of identified CYP1A1 inhibitors with the crystal 
structure of CYP1A1 (PDB ID: 4I8V)18 was performed using the protocol as described earlier.10, 12  
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